Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $4.08

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price gapped up prior to trading on Monday . The stock had previously closed at $4.08, but opened at $4.23. Autolus Therapeutics shares last traded at $3.91, with a volume of 289,854 shares.

Analyst Ratings Changes

AUTL has been the subject of a number of recent research reports. William Blair reiterated an “outperform” rating on shares of Autolus Therapeutics in a research report on Monday, June 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 target price on shares of Autolus Therapeutics in a report on Monday, June 17th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Autolus Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $8.70.

Autolus Therapeutics Stock Down 4.0 %

The firm has a 50-day moving average of $4.10 and a two-hundred day moving average of $4.43. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -3.20 and a beta of 2.05. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). As a group, sell-side analysts anticipate that Autolus Therapeutics plc will post -0.84 earnings per share for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Wealth Effects LLC boosted its holdings in Autolus Therapeutics by 19.5% during the second quarter. Wealth Effects LLC now owns 49,000 shares of the company’s stock valued at $171,000 after acquiring an additional 8,000 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Autolus Therapeutics by 66.2% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 27,034 shares of the company’s stock worth $172,000 after buying an additional 10,771 shares during the period. EntryPoint Capital LLC lifted its holdings in shares of Autolus Therapeutics by 113.6% during the first quarter. EntryPoint Capital LLC now owns 21,540 shares of the company’s stock worth $137,000 after buying an additional 11,456 shares during the last quarter. ProShare Advisors LLC acquired a new stake in shares of Autolus Therapeutics in the second quarter worth $43,000. Finally, Privium Fund Management B.V. increased its position in Autolus Therapeutics by 43.2% during the first quarter. Privium Fund Management B.V. now owns 50,058 shares of the company’s stock worth $319,000 after acquiring an additional 15,091 shares during the period. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.